Midostaurin approved for FLT3-mutated AML

Mark Levis

doi:10.1182/blood-2017-05-782292

Midostaurin approved for FLT3-mutated AML

Mark Levis

School of Medicine

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.

Original language	English (US)
Pages (from-to)	3403-3406
Number of pages	4
Journal	Blood
Volume	129
Issue number	26
DOIs	https://doi.org/10.1182/blood-2017-05-782292
State	Published - Jun 29 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-05-782292

Cite this

@article{dd409e93a0784e0ebe77bf07353cdf09,

title = "Midostaurin approved for FLT3-mutated AML",

abstract = "Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.",

author = "Mark Levis",

note = "Publisher Copyright: {\textcopyright} 2017 by The American Society of Hematology.",

year = "2017",

month = jun,

day = "29",

doi = "10.1182/blood-2017-05-782292",

language = "English (US)",

volume = "129",

pages = "3403--3406",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "26",

}

TY - JOUR

T1 - Midostaurin approved for FLT3-mutated AML

AU - Levis, Mark

PY - 2017/6/29

Y1 - 2017/6/29

N2 - Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.

AB - Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.

UR - http://www.scopus.com/inward/record.url?scp=85021760539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021760539&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-05-782292

DO - 10.1182/blood-2017-05-782292

M3 - Article

C2 - 28546144

AN - SCOPUS:85021760539

SN - 0006-4971

VL - 129

SP - 3403

EP - 3406

JO - Blood

JF - Blood

IS - 26

ER -

Midostaurin approved for FLT3-mutated AML

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this